These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874 [TBL] [Abstract][Full Text] [Related]
3. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967 [TBL] [Abstract][Full Text] [Related]
4. The genomic landscape of childhood and adolescent melanoma. Lu C; Zhang J; Nagahawatte P; Easton J; Lee S; Liu Z; Ding L; Wyczalkowski MA; Valentine M; Navid F; Mulder H; Tatevossian RG; Dalton J; Davenport J; Yin Z; Edmonson M; Rusch M; Wu G; Li Y; Parker M; Hedlund E; Shurtleff S; Raimondi S; Bhavin V; Donald Y; Mardis ER; Wilson RK; Evans WE; Ellison DW; Pounds S; Dyer M; Downing JR; Pappo A; Bahrami A J Invest Dermatol; 2015 Mar; 135(3):816-823. PubMed ID: 25268584 [TBL] [Abstract][Full Text] [Related]
5. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424 [TBL] [Abstract][Full Text] [Related]
6. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis. Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485 [TBL] [Abstract][Full Text] [Related]
7. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients. Jia DD; Li T Sci Rep; 2024 Jul; 14(1):16607. PubMed ID: 39025927 [TBL] [Abstract][Full Text] [Related]
16. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687 [TBL] [Abstract][Full Text] [Related]
17. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
18. Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma. Sheen YS; Chu CY Br J Dermatol; 2021 Mar; 184(3):390-391. PubMed ID: 33448329 [No Abstract] [Full Text] [Related]
19. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis. Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376 [TBL] [Abstract][Full Text] [Related]